Objective: [64Cu]Cu-ATSM is a radiotherapeutics under clinical trials. It is necessary to take appropriate measures to limit its exposure and ensures its airborne concentrations do not exceed legally permitted levels. Therefore, the purpose of this study was to measure the airborne radioactivity concentration in the inpatient room after administering [64Cu]Cu-ATSM to patients.
Methods: Three patients with malignant glioma were intravenously administered [64Cu]Cu-ATSM (100 MBq/kg ± 10%) in an inpatient room, and the airborne radioactivity concentrations were measured at two locations in the room (in the center of the room and near the entrance of the room) using a filter collection method.
Results: After administration of [64Cu]Cu-ATSM, the airborne radioactivity concentrations measured were around or below the limit of detection (8.24×10-7 Bq/cm3 or lower) in all three patients, and all concentrations were consistently below 1/10,000 of the legal airborne concentration limit of 64Cu (1×10-1 Bq/cm3).
Conclusion: The results of this study confirmed that the airborne concentration of [64Cu]Cu-ATSM after administration to patients was below the legally permitted level.
{"title":"[Measurement of Airborne Radioactivity in the Inpatient Room after Administering [<sup>64</sup>Cu]Cu-ATSM to Patients].","authors":"Kimiteru Ito, Hiroaki Kurihara, Hiroki Matsumoto, Tomoko Tachibana, Yukie Yoshii, Yoshitaka Narita, Makoto Hosono","doi":"10.18893/kakuigaku.oa.2501","DOIUrl":"10.18893/kakuigaku.oa.2501","url":null,"abstract":"<p><strong>Objective: </strong>[<sup>64</sup>Cu]Cu-ATSM is a radiotherapeutics under clinical trials. It is necessary to take appropriate measures to limit its exposure and ensures its airborne concentrations do not exceed legally permitted levels. Therefore, the purpose of this study was to measure the airborne radioactivity concentration in the inpatient room after administering [<sup>64</sup>Cu]Cu-ATSM to patients.</p><p><strong>Methods: </strong>Three patients with malignant glioma were intravenously administered [<sup>64</sup>Cu]Cu-ATSM (100 MBq/kg ± 10%) in an inpatient room, and the airborne radioactivity concentrations were measured at two locations in the room (in the center of the room and near the entrance of the room) using a filter collection method.</p><p><strong>Results: </strong>After administration of [<sup>64</sup>Cu]Cu-ATSM, the airborne radioactivity concentrations measured were around or below the limit of detection (8.24×10<sup>-7</sup> Bq/cm<sup>3</sup> or lower) in all three patients, and all concentrations were consistently below 1/10,000 of the legal airborne concentration limit of <sup>64</sup>Cu (1×10<sup>-1</sup> Bq/cm<sup>3</sup>).</p><p><strong>Conclusion: </strong>The results of this study confirmed that the airborne concentration of [<sup>64</sup>Cu]Cu-ATSM after administration to patients was below the legally permitted level.</p>","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"62 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Internal radiation therapy using Lutetium-177 (177Lu)-PSMA-617 will be approved for PSMA-positive castration-resistant prostate cancer in actual clinical practice soon. At present, NHI medical technical fee for the use of Lutetium-177 (177Lu)-PSMA-617 injection has not been set. The Japanese Society of Nuclear Medicine conducted a health resource use survey in internal radiation therapy using a questionnaire sent to medical institutions which conducted clinical trials. As a result of the investigation, the cost required for treatment management per patient is 1,752,860 JPY, based on the Draft Proposal for Medical Examination Value (Ver.7.4) of the Japanese Health Insurance Federation for Surgery. Lutetium-177 (177Lu)-PSMA-617 is required to be administered every 6 weeks up to 6 times, and the treatment management fee per administration was estimated to be 292,143 JPY and the appropriate NHI medical technical fee is 29,214 points per patient per treatment, which can be claimed 6 times. In addition, Ga-generator and [68Ga] Ga-PSMA-11 elution/preparation work are required for PSMA-PET diagnosis, which is necessary for judging the appropriateness of administration of Lutetium-177 (177Lu)-PSMA-617. It was considered necessary to set an additional cost of 123,083 JPY per patient as the management expenses of Ga-generator, and 12,308 points per 1 administration was considered appropriate as the NHI medical technical fee.
{"title":"[A Report on Health Resource Use in Internal Radiation Therapy Using Lutetium-177 (<sup>177</sup>Lu)-PSMA-617].","authors":"Shoko Takano, Tatsuya Higashi, Katsuhiko Kato, Ryogo Minamimoto, Yuta Akisawa, Yoshinori Matoba, Seigo Kinuya","doi":"10.18893/kakuigaku.tr.2504","DOIUrl":"https://doi.org/10.18893/kakuigaku.tr.2504","url":null,"abstract":"<p><p>Internal radiation therapy using Lutetium-177 (<sup>177</sup>Lu)-PSMA-617 will be approved for PSMA-positive castration-resistant prostate cancer in actual clinical practice soon. At present, NHI medical technical fee for the use of Lutetium-177 (<sup>177</sup>Lu)-PSMA-617 injection has not been set. The Japanese Society of Nuclear Medicine conducted a health resource use survey in internal radiation therapy using a questionnaire sent to medical institutions which conducted clinical trials. As a result of the investigation, the cost required for treatment management per patient is 1,752,860 JPY, based on the Draft Proposal for Medical Examination Value (Ver.7.4) of the Japanese Health Insurance Federation for Surgery. Lutetium-177 (<sup>177</sup>Lu)-PSMA-617 is required to be administered every 6 weeks up to 6 times, and the treatment management fee per administration was estimated to be 292,143 JPY and the appropriate NHI medical technical fee is 29,214 points per patient per treatment, which can be claimed 6 times. In addition, Ga-generator and [<sup>68</sup>Ga] Ga-PSMA-11 elution/preparation work are required for PSMA-PET diagnosis, which is necessary for judging the appropriateness of administration of Lutetium-177 (<sup>177</sup>Lu)-PSMA-617. It was considered necessary to set an additional cost of 123,083 JPY per patient as the management expenses of Ga-generator, and 12,308 points per 1 administration was considered appropriate as the NHI medical technical fee.</p>","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"62 1","pages":"71-87"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.18893/kakuigaku.62.S1
{"title":"[Joint Program].","authors":"","doi":"10.18893/kakuigaku.62.S1","DOIUrl":"https://doi.org/10.18893/kakuigaku.62.S1","url":null,"abstract":"","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"62 Supplement","pages":"S1-S8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145453083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.18893/kakuigaku.62.S63
{"title":"[Special Program].","authors":"","doi":"10.18893/kakuigaku.62.S63","DOIUrl":"https://doi.org/10.18893/kakuigaku.62.S63","url":null,"abstract":"","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"62 Supplement","pages":"S63-S97"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145453656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.18893/kakuigaku.rp.2431
Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura
This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2022 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,004 institutions out of 1,181 to which the questionnaire had been sent. A total of 911,977 radiopharmaceutical administrations were reported. Seventeen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.9 . No case of defective products was reported.
{"title":"[The 45th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 48th Survey in 2022)].","authors":"Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura","doi":"10.18893/kakuigaku.rp.2431","DOIUrl":"https://doi.org/10.18893/kakuigaku.rp.2431","url":null,"abstract":"<p><p>This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2022 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 1,004 institutions out of 1,181 to which the questionnaire had been sent. A total of 911,977 radiopharmaceutical administrations were reported. Seventeen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.9 . No case of defective products was reported.</p>","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"61 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139934878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.18893/kakuigaku.61.A4
{"title":"","authors":"","doi":"10.18893/kakuigaku.61.A4","DOIUrl":"https://doi.org/10.18893/kakuigaku.61.A4","url":null,"abstract":"","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"61 Supplement","pages":"A4"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.18893/kakuigaku.61.A5
{"title":"","authors":"","doi":"10.18893/kakuigaku.61.A5","DOIUrl":"https://doi.org/10.18893/kakuigaku.61.A5","url":null,"abstract":"","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"61 Supplement","pages":"A5"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.18893/kakuigaku.61.S191
{"title":"[Luncheon Seminar / Sweets Seminar Program].","authors":"","doi":"10.18893/kakuigaku.61.S191","DOIUrl":"https://doi.org/10.18893/kakuigaku.61.S191","url":null,"abstract":"","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"61 Supplement","pages":"S191-S195"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.18893/kakuigaku.wgr.2432
{"title":"","authors":"","doi":"10.18893/kakuigaku.wgr.2432","DOIUrl":"10.18893/kakuigaku.wgr.2432","url":null,"abstract":"","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"61 1","pages":"13-14"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139992238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.18893/kakuigaku.arm.2434
{"title":"","authors":"","doi":"10.18893/kakuigaku.arm.2434","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2434","url":null,"abstract":"","PeriodicalId":94120,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"61 1","pages":"19-26"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号